Biotech Values

[DewDiligence]

(RVNC)—A load of BS from AGN:

https://www.fiercepharma.com/pharma/look-out-allergan-doc-surveys-show-botox-competitive-threat-real

Allergan, for its part, isn’t convinced that “longer lasting” necessarily means “better” when it comes to [botulinum toxin] product selection. Patients have more freedom to choose their timing with a shorter-acting product. “When you have the ability to take a treatment and then you get to control when you take your next treatment, that’s a certain amount of balance,” Mitchell Brin, Allergan’s Chief Scientific Officer for Botox, said in an interview during the J.P. Morgan Healthcare Conference earlier this month.

Hahaha.